Quick Answer
Aptose Biosciences Inc. reported R&D Expense of $11.34 million for fiscal year 2025.
Aptose Biosciences Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $11.34M | -24.9% |
| 2024 | $15.10M | -54.6% |
| 2023 | $33.27M | +35.6% |
| 2022 | $24.53M | -46.7% |
| 2021 | $45.98M | +57.0% |
| 2020 | $29.29M | +74.0% |
| 2019 | $16.84M | -10.1% |
| 2018 | $18.73M | +198.6% |
| 2017 | $6.27M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.21M | -53.1% | -33.1% |
| June 30, 2025 | $3.30M | -25.3% | +39.5% |
| March 31, 2025 | $2.36M | -63.3% | -49.7% |
| September 30, 2024 | $4.70M | -43.0% | +6.5% |
| June 30, 2024 | $4.41M | -58.3% | -31.5% |
| March 31, 2024 | $6.45M | -26.9% | -21.9% |
| September 30, 2023 | $8.26M | +25.5% | -22.0% |
| June 30, 2023 | $10.58M | +44.1% | +20.1% |
- Aptose Biosciences Inc. showed a decrease of -24.9% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, Aptose Biosciences Inc.’s r&d expense has grown by 80.8% (from $6.27 million to $11.34 million).
- The most recent figure is from Aptose Biosciences Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: